The latest biotech news

News and Trends 12 Aug 2015

A Tale of Love for UniQure and Bristol-Myers Squibb

In May, Bristol-Myers Squibb (BMS) nailed down the exclusive access to uniQure’s gene therapy platform to treat cardiovascular diseases. Everything seems to work out fine as BMS paid $53M (€47M) for three new targets and additional shares to own nearly 10% of the company. UniQure is a Dutch pioneer in the field of gene therapy. It […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

Roche‘s subsidiary Genentech joined forces with NASDAQ-listed Clovis Oncology to evaluate a novel combination therapy for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). Its anti PD-L1 cancer immunotherapy and Clovis’ rociletinib will enter Phase Ib/II in 2015. With 1.35 million new cases annually, lung cancer is the most common cancer worldwide. In […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership team with Samarth Kulkarni as its new Chief Business Officer and Michael Bruce as Senior Vice President to moderate program portfolio and alliance management. In the meantime, CRISPR’s main competitor EditasMedicine procured €108M to accelerate its CRISPR-based therapies in clinical state. […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

18-year-old French Hybrigenics goes to the US with its Acute Myeloid Leukemia Treatment

Hybrigenics is one step closer to enter the American market. The FDA granted Orphan Drug designation to the company’s Acute Myeloid Leukemia (AML) Treatment. Currently in preclinical stage, the therapy showed efficacy in combination with two AML-drugs that are already approved. AML is the second most frequent form of leukemia and accounts for about 30% […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

Pili Printed their First Page with Bacteria-Made Ink!

Pili is a group of seven young dedicated entrepreneurs that dream of replacing the toxic pigments used in today’s ink with natural, non-toxic, recyclable ink made by bacteria. A dream that could soon become reality as the start-up just achieved the first proof of concept and printed its first page with a bacteria-made biodegradable ink! It […]

August 11, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

The massive expansion of AstraZeneca’s pipeline continues, as its biological subsidiary, MedImmune buys Inovio Pharmaceuticals‘ clinical-stage cancer vaccine that targets cancer caused by the human papillomavirus (HPV). MedImmune, which makes up nearly 50% of AstraZeneca’s pipeline, may spend over $720M (€653M) to bolster its cancer-associated portfolio. HPV is the most commonly sexually transmitted virus and […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M

Oxitec‘s self-limiting gene technique, which is designed to exterminate dangerous insects, has a price now: $160M (€146M). US-based Intrexon absorbed the Oxford University’s spinout with its unique technology to accelerate the crackdown of dengue infections and crop damages. As we reported early this year, Intrexon Corporation recently partnered across diverse markets, all being part of […]

August 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. […]

August 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 9 Aug 2015

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections. The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and […]

August 9, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 7 Aug 2015

Bill & Melinda Gates’ Faith in CureVac is Leading to a New Program

CureVac, a pioneer in the field of mRNA-based technology, today announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation. The program will leverage CureVac’s RNActive technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV), adding to […]

August 7, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 6 Aug 2015

Aging-diseases expert Biophytis launches its IPO in Paris

[Update August 6th, 2015] A month after its Initial Public Offering in Paris, Biophytis just announced that the company raised an extra €6 million from a North-American investor. This fresh money is joining the €10 million successfully raised by the French biotech on July 8th, 2015. Original article published on June 26th, 2015: The Parisian biotech Biophytis […]

August 6, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

A Tale of Love for UniQure and Bristol-Myers Squibb

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

18-year-old French Hybrigenics goes to the US with its Acute Myeloid Leukemia Treatment

Pili Printed their First Page with Bacteria-Made Ink!

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Bill & Melinda Gates’ Faith in CureVac is Leading to a New Program

Aging-diseases expert Biophytis launches its IPO in Paris

Subscribe to our newsletter to get the latest biotech news!